What Does Retatrutide Do? How the Triple-Agonist Works

Published on: May 22, 2026

Medically reviewed by

Ashis Tandukar

Superintendent Pharmacist · Reg: GPhC No. 2084170

Most people first hear about retatrutide in a headline that goes something like "the next big weight-loss drug" — and then immediately want to know what it actually does. Not the marketing version. The clinical version. The version their GP might explain.

That's what this guide is for. Retatrutide is still in clinical trials, but the published data is detailed enough that we can give you a proper answer.

The basics: what retatrutide is

Retatrutide is an investigational weekly injection being developed by Eli Lilly for weight loss and related metabolic conditions. It is not yet licensed by the MHRA in the UK or the FDA in the US. Trials are ongoing, with results so far published in The New England Journal of Medicine and other peer-reviewed sources.

What sets it apart is its mechanism. Where Wegovy (semaglutide) targets one hormone receptor, and Mounjaro (tirzepatide) targets two, retatrutide targets three. That's why it's sometimes called a triple-agonist or, more informally, "triple G".

The three receptors are GLP-1, GIP and glucagon. Each does something different inside the body. Retatrutide nudges all of them at once. We've written a separate explainer on why retatrutide doesn't have a brand name yet if you've been searching for one.

How retatrutide works inside the body

To understand what retatrutide does, you have to understand what those three hormones do on their own. They were not invented by a drug company — they are already inside you, doing this work every day. Retatrutide just amplifies the effect.

GLP-1 (glucagon-like peptide-1)

GLP-1 is the same hormone targeted by Ozempic, Wegovy and Mounjaro. On its own, GLP-1 does several useful things. It slows the rate at which your stomach empties, so meals make you feel fuller for longer. It tells your pancreas to release insulin when blood sugar rises after eating. And it acts directly on appetite centres in the brain to reduce hunger and quiet what many patients describe as "food noise" — the running mental commentary about what to eat next.

Retatrutide activates the same GLP-1 receptors. That part of the drug feels familiar to anyone who has used existing GLP-1 medications.

GIP (glucose-dependent insulinotropic polypeptide)

GIP is the second hormone Mounjaro targets, and it complements GLP-1. It helps the body release insulin in response to food, but it also seems to make fat tissue more efficient at storing energy in the right places — rather than around the liver or the abdomen.

Clinically, adding GIP appears to improve both blood sugar control and weight loss outcomes, which is why dual-agonists like Mounjaro outperform single GLP-1 drugs in head-to-head trials. If you want to see how this plays out in patients, our piece on how Mounjaro affects hormones, hunger and the brain goes into the detail.

Glucagon

This is the receptor that makes retatrutide different from anything currently licensed. Glucagon is best known for raising blood sugar — but it also has another role most people don't realise: it increases resting energy expenditure. In simple terms, it can nudge your metabolism upwards.

Activating glucagon at the same time as GLP-1 and GIP appears to do two things in trials. People eat less. And they burn slightly more energy at rest. That combination is hard to achieve with diet alone — and it's the engine behind the unusually large weight reductions retatrutide produces.

What retatrutide does to appetite

Ask any clinician who has prescribed GLP-1 medications and they will tell you the same thing. The change patients notice first usually isn't the scale — it's the relief from constant thinking about food.

Retatrutide does this in the same way Mounjaro and Wegovy do, but the early trial data suggests the effect is even more pronounced. Hunger drops. Cravings soften. The desire to snack between meals tends to fade. Many patients describe being able to leave food on the plate for the first time in years.

This is the part most people underestimate before starting any GLP-1-based treatment. When food no longer dominates your thinking, healthier choices stop feeling like a daily battle.

If you want to understand this in more depth, our guide on food noise and how it works breaks it down with real patient examples.

What retatrutide does to body weight

This is the part that has made retatrutide the most talked-about weight-loss drug in development.

The pivotal Phase 2 trial — a 48-week study published in The New England Journal of Medicine in 2023 — produced these results in adults with obesity (and no diabetes), at the highest dose of 12 mg weekly:

• Average weight loss of around 24% from baseline
• A clear dose-response, with even the 4 mg dose producing roughly 17% weight loss
• Continued weight loss right up to the 48-week endpoint, with no plateau in sight

For context, similar Phase 2 data for Wegovy showed around 15% weight loss at 68 weeks. Mounjaro's pivotal trial showed 20-22% at 72 weeks. Retatrutide is producing larger losses, faster.

That's striking — but worth treating with appropriate caution. Phase 2 trials are smaller, and Phase 3 results (in larger and more diverse populations) sometimes come in slightly lower. The full Phase 3 programme, called TRIUMPH, is still running. Real-world figures may differ from the headline trial numbers.

Our deeper breakdown of retatrutide trial results covers the dose-by-dose data in more detail.

What retatrutide does for blood sugar and diabetes

Retatrutide is being trialled as a treatment for type 2 diabetes as well as obesity. In Phase 2 trials for diabetes:

• HbA1c (the standard 3-month blood sugar marker) dropped by around 2.0 percentage points at the higher doses
• Many patients reached the standard treatment target of HbA1c below 7%
• Weight loss was preserved alongside the glucose improvements

Combining all three receptors means retatrutide can lower blood sugar, encourage weight loss, and improve insulin sensitivity at the same time. For someone living with both obesity and type 2 diabetes — a combination affecting millions of people in the UK — that's an unusually complete profile.

What it does for the liver

The third area where retatrutide is showing real promise is non-alcoholic fatty liver disease (NAFLD) and its more serious form, MASH (metabolic dysfunction-associated steatohepatitis).

In a 48-week sub-study, around 80-90% of participants on retatrutide saw liver fat fall to levels considered normal on imaging. That's a meaningful drop, especially given that liver disease is closely linked to obesity and insulin resistance — and that no medication is currently licensed in the UK to treat MASH directly.

A caveat. Trial endpoints are not always reflective of long-term outcomes, and biopsy-confirmed liver improvement still needs to be demonstrated at scale. But the signal is real.

What retatrutide does to side effects

No medication does only the good things, and retatrutide is no exception. The side effect profile mirrors what you'd expect from GLP-1-based drugs:

• Nausea, particularly when starting or increasing the dose
• Diarrhoea and, less often, constipation
• Reduced appetite (which is, of course, partly the point)
• Tiredness in the first few weeks
• Occasional vomiting at higher doses

In the Phase 2 trials, most side effects were rated mild to moderate and tended to settle as the body adjusted. The drug is started at a low dose and titrated upwards over several months — partly to manage these effects.

The glucagon component adds one consideration unique to retatrutide: a small increase in resting heart rate, typically by a few beats per minute. This is being monitored closely in Phase 3, and is something a prescribing clinician would need to assess individually.

For a more thorough rundown, our piece on retatrutide side effects walks through the trial data in detail.

What retatrutide doesn't do

It's worth being honest about what retatrutide is not.

It is not a substitute for the lifestyle work that supports lasting weight loss. The drug reduces appetite and helps the body use food more efficiently. It doesn't choose what you eat, and it doesn't move you. The patients who do best on any GLP-1-based medication are the ones who use the appetite reduction as an opportunity to rebuild the habits around food, protein intake, sleep and movement.

It is also not a quick fix. Trial dosing typically runs for at least 48 weeks, and many specialists believe meaningful weight loss treatment will be open-ended in the same way as treatments for blood pressure or cholesterol.

And it is not yet available on prescription. As of 2026, retatrutide is investigational only. Anything sold online claiming to be "retatrutide for weight loss" outside a regulated clinical trial is not a licensed medicine — and may not contain what it claims. Our UK availability guide covers this in detail, including the safety risks involved.

How retatrutide compares to current options

A short comparison helps put the mechanism in context.

If you want to step back and look at the wider picture, our overview of weight loss medication in the UK covers what is currently licensed and how the options compare across price, eligibility and clinical evidence.

When retatrutide might be available in the UK

Eli Lilly has begun the regulatory groundwork, with UK and EU approvals expected within roughly 18-24 months, subject to the MHRA's normal process. The most likely route to access in the UK, once approved, will be through regulated online pharmacies and weight loss clinics — initially privately, before any consideration of NHS funding.

If you're thinking about retatrutide because of what you've read in the news, it's worth knowing this. The current best-in-class licensed treatment — Mounjaro — already produces results that meaningfully change health outcomes for most people. There is no need to wait if you'd benefit from treatment now.

We've covered the current access picture for retatrutide in the UK and the routes people are exploring to get hold of it — including the safety considerations involved in anything outside a regulated supply chain.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any treatment.